Crystalline forms of niraparib tosylate
AssigneeApotex Inc.
InventorsAlexander J. Stirk, Fabio E. S. Souza, Avedis Karadeolian, Allan W. Rey
Life of this patent
Estimating the term…
Abstract
The present invention provides novel crystalline forms of niraparib tosylate. Specific crystalline forms provided by the present invention include niraparib tosylate Form APO-I, a co-crystal of niraparib tosylate and urea, and niraparib tosylate Form APO-II, a co-crystal of niraparib tosylate and oxalic acid. Also provided are pharmaceutical compositions including the niraparib tosylate crystalline forms, and the use of these forms in treatment or prevention of conditions which can be ameliorated by the inhibition of poly(ADP-ribose) polymerase (PARP), in particular certain forms of cancer.
Claims20
A crystalline form of niraparib tosylate comprising niraparib tosylate and urea.
A crystalline form of niraparib tosylate comprising niraparib tosylate and oxalic acid.
Dependencies are inferred from the claim text.